156 related articles for article (PubMed ID: 37011230)
21. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
22. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
[TBL] [Abstract][Full Text] [Related]
23. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH; Tobin JWD; Seo YD; Gener-Ricos G; Keung EZ; Burton EM; Davies MA; McQuade JL; Lazar AJ; Mason R; Millward M; Sandhu S; Khoo C; Warburton L; Guerra V; Haydon A; Dearden H; Menzies AM; Carlino MS; Smith JL; Mollee P; Burgess M; Mapp S; Keane C; Atkinson V; Parikh SA; Markovic SN; Ding W; Call TG; Hampel PJ; Long GV; Wargo JA; Ferrajoli A
Ann Oncol; 2023 Sep; 34(9):796-805. PubMed ID: 37414216
[TBL] [Abstract][Full Text] [Related]
25. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias A; Merseburger A; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627145
[TBL] [Abstract][Full Text] [Related]
26. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
[TBL] [Abstract][Full Text] [Related]
28. MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
Bhatia A; Birger M; Veeraraghavan H; Um H; Tixier F; McKenney AS; Cugliari M; Caviasco A; Bialczak A; Malani R; Flynn J; Zhang Z; Yang TJ; Santomasso BD; Shoushtari AN; Young RJ
Neuro Oncol; 2019 Dec; 21(12):1578-1586. PubMed ID: 31621883
[TBL] [Abstract][Full Text] [Related]
29. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
30. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Brown J; Hitron EE; Russler GA; Caulfield S; Kissick H; Alemozaffar M; Ogan K; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Cancer Med; 2020 Apr; 9(8):2752-2760. PubMed ID: 32100417
[TBL] [Abstract][Full Text] [Related]
31. PILE: a candidate prognostic score in cancer patients treated with immunotherapy.
Guven DC; Yildirim HC; Bilgin E; Aktepe OH; Taban H; Sahin TK; Cakir IY; Akin S; Dizdar O; Aksoy S; Yalcin S; Erman M; Kilickap S
Clin Transl Oncol; 2021 Aug; 23(8):1630-1636. PubMed ID: 33586122
[TBL] [Abstract][Full Text] [Related]
32. Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.
Diker O; Olgun P; Balyemez U; Sigit Ikiz S
Cureus; 2023 Jan; 15(1):e33234. PubMed ID: 36733552
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
36. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
37. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
38. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
39. An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy-a retrospective cohort study examining 66 circulating immune cell subsets.
Chi P; Jiang H; Li D; Li J; Wen X; Ding Q; Chen L; Zhang X; Huang J; Ding Y
Front Immunol; 2022; 13():1012673. PubMed ID: 36569825
[TBL] [Abstract][Full Text] [Related]
40. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
